0HOJ.L - Blueprint Medicines Corporation Stock Price & Dividend Safety Sector: Healthcare | Exchange: London Stock Exchange Current Price & Safety Score Price: 129.40 USD StockBonds Safety Grade: Altman Z-Score (Bankruptcy Risk): 2.10 StockBond Score: 3.19 Company Description Blueprint Medicines Corporation a precision therapy company develops medicines for genomically defined cancers and blood disorders in the United States and internationally The company is developing AYVAKIT for the treatment of systemic mastocytosis SM and gastrointestinal stromal tumors BLU263 an orally available potent and KIT inhibitor for the treatment of nonadvanced SM and other mast cell disorders and Fisogatinib an orally available and potent inhibitor for the treatment of hepatocellular carcinoma It is also developing GAVRETO for the treatment of RET fusionpositive nonsmall cell lung cancer altered solid tumors medullary thyroid carcinoma and other solid tumors BLU701 and BLU945 for the treatment of epidermal growth factor receptor driven nonsmallcell lung carcinoma NSCLC and BLU451 to treat NSCLC in patients with epidermal growth factor receptor gene EGFR exon 20 insertion mutations In addition the company is developing BLU782 for the treatment of fibrodysplasia ossificans progressive BLU 222 to treat patients with cyclin E aberrant cancers and BLU852 for the treatment of advanced cancers It has collaboration and license agreements with Clementia Pharmaceuticals Inc Proteovant Therapeutics CStone Pharmaceuticals Genentech Inc F HoffmannLa Roche Ltd and HoffmannLa Roche Inc and Zai Lab Shanghai Co Ltd The company was formerly known as Hoyle Pharmaceuticals Inc and changed its name to Blueprint Medicines Corporation in June 2011 Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge Massachusetts